Phase 1 Study to Assess Safety, Drug Behavior, and Effectiveness of SC-102 in Adults With Advanced or Metastatic Solid Tumors Expressing EphA2

What this Trial Is About

Researchers are evaluating SC-102, a peptide drug conjugate targeting EphA2, in people with advanced or metastatic solid tumors that express this protein. This phase I, multi-center, open-label trial aims to assess the safety, pharmacokinetics how the drug moves through the body, and anti-cancer effects of SC-102. The study includes both a dose escalation phase to find safe and tolerable doses and a dose expansion phase to evaluate clinical activity of the drug. Participants will receive SC-102 either once weekly or once every two weeks as a single treatment during 4-week cycles. The dose escalation part determines the recommended doses for the expansion phase. The dose expansion phase focuses on measuring the drugs clinical impact. Treatment continues until disease progression, unacceptable side effects, or other criteria are met. Throughout the study, participants will be closely monitored with safety assessments including treatment-emergent adverse events. Researchers will evaluate responses using established criteria for solid tumors and measure drug levels in the blood. Follow-up may continue for up to two years to assess outcomes like duration of response and disease control. This comprehensive monitoring helps understand SC-102s effects and safety profile in this patient population.

Study of SC-102 in Patients With Advanced Solid Tumors